Example: confidence

審査情報提供事例について - ssk.or.jp

Mg .. mg .. mg .. ) .. 5 10 .. Zollinger-Ellison .. Zollinger-Ellison .. Zollinger-Ellison .. 12 .. 12 . 12 .. 12 .. 12 .. 12 12 .. ) .. ( ) .. ( ) .. - .. 150 150 150.. 150 .. ( ) .. ( ) .. 1000/ 2000/ .. 500/ 1000/.. ( .. 40 125 500 1000 .. 40 125 .. 40 125 500 .. 40mg 125mg 500mg 1000mg .. Churg-Strauss .. 40mg 125mg 500mg . 1000mg .. - .. ( ) . ( ) ( ) . ( ).. ( ) . ( ) . ( ) ( . ) . ( ) ( . ) . ( ) .. ( ) . ( ) .. ( ). ( ) ( . )( . ) ( ) ( . ) .. ( ). ( ). ( )( . ) . ( ) . ( ) .. ( . ) ( ) .. ( ). ( ).. ( ) . ( .. )( . ) ( )( ) . ( ) . ( . ) ( ) . ( )( . ) . ( . ) ( . Senear-Usher ) . ( ) ( ) . ( ). ( )( . ). ( .. ) . ( ).. ( ) . ( ) .. ( ). ( ) ( . ) .. ( ) ( ) . ( ).. ( ).. ( ) ( ) . ( ) ( ).. ( ) ( ) . ( ).. ( )( ). ( ) . ( ) .. ( ) .. ( ) .. ( ) .. ( ) .. 1 .. 125 250 125 250 .. BNS .. REM .. Yahr .. MAO-B B . - .. L-dopa .. Yahr . Yahr .. L-dopa.

50 チクロピジン塩酸塩①(循環器科3) 《平成19年9月21日新規》 《平成26年9月22日更新》

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Other abuse

Transcription of 審査情報提供事例について - ssk.or.jp

1 Mg .. mg .. mg .. ) .. 5 10 .. Zollinger-Ellison .. Zollinger-Ellison .. Zollinger-Ellison .. 12 .. 12 . 12 .. 12 .. 12 .. 12 12 .. ) .. ( ) .. ( ) .. - .. 150 150 150.. 150 .. ( ) .. ( ) .. 1000/ 2000/ .. 500/ 1000/.. ( .. 40 125 500 1000 .. 40 125 .. 40 125 500 .. 40mg 125mg 500mg 1000mg .. Churg-Strauss .. 40mg 125mg 500mg . 1000mg .. - .. ( ) . ( ) ( ) . ( ).. ( ) . ( ) . ( ) ( . ) . ( ) ( . ) . ( ) .. ( ) . ( ) .. ( ). ( ) ( . )( . ) ( ) ( . ) .. ( ). ( ). ( )( . ) . ( ) . ( ) .. ( . ) ( ) .. ( ). ( ).. ( ) . ( .. )( . ) ( )( ) . ( ) . ( . ) ( ) . ( )( . ) . ( . ) ( . Senear-Usher ) . ( ) ( ) . ( ). ( )( . ). ( .. ) . ( ).. ( ) . ( ) .. ( ). ( ) ( . ) .. ( ) ( ) . ( ).. ( ).. ( ) ( ) . ( ) ( ).. ( ) ( ) . ( ).. ( )( ). ( ) . ( ) .. ( ) .. ( ) .. ( ) .. ( ) .. 1 .. 125 250 125 250 .. BNS .. REM .. Yahr .. MAO-B B . - .. L-dopa .. Yahr . Yahr .. L-dopa.

2 L-dopa .. 2 . 2 .. 40mg 125mg 500mg 1000mg .. 40mg 125mg . 40mg 125mg 500mg .. CIDP .. PSS . ADEM .. / .. 40mg 125mg 500mg 1000mg .. Churg-Strauss .. 10 .. 11 .. 12 .. 13 .. 14 .. 15 .. 16 .. 17 .. 18 .. 19 .. 20 .. 21 .. Senear-Usher .. 23 .. 23 .. 24 .. Churg-Strauss . / .. CIDP .. Fanconi Wiskott-Aldrich Hunter .. Churg-Strauss . / .. CIDP .. ALS .. ALS .. Na .. - .. - .. Positive inotropic . Positive chronotropic .. - .. Low .. - .. 25 25.. 100.. - - .. 40mg 125mg 500mg 1000mg .. 40mg 125mg . 40mg 125mg 500mg .. 40mg 125mg 500mg 1000mg .. Churg-Strauss .. ACTH .. 10 .. 11 .. 12 .. 13 .. 14 .. 15 . 16 .. 17 .. 18 .. 19 .. Senear-Usher .. 20 .. 21 .. 22 .. ACTH .. ( .. ).. Senear-Usher .. 10 .. 11 .. 12 .. 13 .. 14 .. 15 .. 16 .. 17 .. 18 .. 19 .. 20 .. 21 .. Senear-Usher .. 23 .. 23 .. 24 .. LT .. in vitro .. 1 . 2 .. 100 .. 500 1000 .. in vitro.

3 MALT .. Na .. 20 .. 100 .. 20mg .. GIK .. N . Ca P .. 5 . A3 .. 5 50 .. 50 .. GVHD .. MALT .. Ca Ca .. Ca . ATP .. Ca . slow channel . Ca .. in vitro .. FN .. in vitro .. TIA . CABG PTCA .. 1.. 2.. 3.. ACTH .. 4.. 1.. 2.. 3.. 1.. 2.. 1.. 2.. 3.. 4.. 5.. 1.. 2.. 1.. 2.. 3.. 1.. 2.. 1.. 2.. 3.. 4.. 1.. 2.. 3.. 1.. 2.. 1.. 2.. 3.. 4.. 1.. 2.. 3.. 4.. 5.. 6.. 7.. 1.. 2.. 3.. 1.. 2.. 1.. 2.. Senear-Usher .. 3.. 4.. 5.. 1.. 2.. 3.. 1.. 2.. 3.. 4.. 5.. 6.. 7.. 8.. 9.. 10.. 11.. 12.. 13.. D .. d- .. d- .. d- .. DNA .. MAC .. MALT .. 2011 . 3- 123 I .. 3- 123 I .. MIBG-I123 .. MIBG .. 3- 123 I .. 2010 .. G .. 1 30 60 1 2 4 .. 1 400 1 6 .. 1 400 1 6 .. 1 500 1 3000 .. 1 300 400 1 6 .. 1 400 4 .. 2007 .. G .. 1 30 60 1 2 4 .. 1 400 1 6 .. 1 400 1 6 .. 1 500 1 3000 .. 1 300 400 1 6 .. 1 200 400 4 6 .. 2007 .. S .. 2007 .. MALT .. 2010 .. 1g . 2g .. 1 100 200mg( )/kg 3.

4 4 .. 1 400mg( )/kg .. 1 50 200mg( )/kg 2. 4 .. 1 1 2g 1 2 .. 1 1 4g 1 2 . 100 500mL 1 2 .. 1 2g 4 .. 1g . 2g .. 1 100 200mg( )/kg 3. 4 .. 1 400mg( )/kg .. 1 50 200mg( )/kg 2. 4 .. -S .. 1 6g 2 .. 1 3g 2 .. 1 60 150mg /kg 3 4 .. 1 3g 6 .. 2007 .. -S .. 2007 .. -S .. 1 6g 2 .. 1 3g 2 .. 1 60 150mg /kg 3 4 .. 1 3g 6 .. 2007 .. 1 1g kg 20 40mg 2 .. 1 . 3g kg 50mg 3 .. 1 5g kg . 100mg .. 1 2g 8 .. 1 1 2g 2 .. 1 50 100mg /kg 3 4.. 1 4g . 2 4 150mg /kg . 3 4 300mg . /kg .. 1 2g 4 6 .. 1 1 2g 2 . 1 4g . 2 4 . 1 40 100mg /kg 2 4 . 1 . 150mg /kg 2 4 . 0 3 1 20mg . /kg 1 2 3 4 1 20mg . /kg 1 3 4 . 1 150mg /kg 2 4 .. 30 2 .. 1 2g 8 .. NCCN 2006 1. National Comprehensive Cancer Network .. 1 2 4g 2 4.. 1 50 125mg /kg 2 4 .. 1 8g . 1 200mg /kg .. 1 2g 100 500mL. 1 2 .. 1 3g 6 .. 3 .. 14 .. 1 1g 2 3 . 30 . 1 1g 1 3g . 1 30 60mg /kg 3 . 30 . 1 120mg /kg . 1 3g .. 1 3g 3 30.

5 1 120mg /kg 3 . 30 1 3g .. 1 2g 8 .. Q .. Q .. 2010 .. DNA .. 3 .. Na .. 3 .. 20 .. 2mg/mL . 2mg/mL .. 2mg/mL .. 2mg/mL.. 2mg/mL .. DNA .. S .. DNA .. 1 100 200 1 2 .. 1 4 8 / 1 2 . 1 . 6 / 1 2 .. 100 500mL 100 200 . 30 1 .. 1 1 .. TIA .. ST .. 2007 .. -L S .. 2005 AHA .. 2002 .. 2002 .. 2002 .. 1 15 30mg 3 .. 3 mg/kg/ 1 3 .. 2002 .. 2002 .. ( ).. ( ).. 50. 1 ( 50mg) 1 1 . 1 1 2 (100mg).. 25. 2 ( 50mg) 1 1 . 1 1 4 (100mg).. 1 .. 2mg/kg 1 1 20.. 25 100 1 1 .. 2010 .. mg .. mg .. Na .. 2mg/kg/ 1 3 .. 2010 .. mL/kg .. mg/kg .. mL/kg . mg/kg .. Na .. 1 10 .. 2010 .. ( ). ( ) .. ( ). 300mg . 450mg .. ( ) . 300mg .. Na .. 5 10mg/kg/ 1 3 .. 2010 .. 1 0 . 125mg/kg/min . 0 . 04mg/kg/min . 0 . 01 0 . 04mg/kg/min .. 1 0 . 06mg/kg/min . 0 . 02mg/kg/min 5. 10 1 0 . 125mg/kg/min 0 . 04mg/kg/min . 0 . 01 0 . 04. mg/kg/min .. 1 .. g/kg/ 80. g/kg/ .. 2010 .. mg .. mg.

6 Mg .. mg .. mg . mg mg mg .. mg .. 1 .. 2010 .. 50kg .. 30 g/kg . 180 g/kg .. 4 1 .. 2011 .. S100 .. S500 S1000 .. S100 . 1 1 kg 100mg 6 8 . S500 S1000 .. 1 1. 5 3. 0g 3 4 .. 1 50 100mg /kg 3 4 .. 1 1. 0 2. 0g 250mL. 500mL 1 2 1 2 .. in vitro .. 1 2 4 6 . 1 8 12g 1 2 4 . 1 12g .. JAID/JSC 2011 .. 5-FU . FduMP DNA .. 5% . (1mL 50 . 500 g . 1 Kg .. 1 5 g/Kg/ .. 5 g/Kg/ .. g/Kg/ . 5 15 . /Kg/ .. g/Kg/ . 5 /Kg/ 1 2 /Kg/. 20 40 /Kg 1 . 1 3 .. 1 60 90 g 100 g .. 2011 / .. 40mg 125mg 500mg 1000mg .. 8 .. 40mg 125mg .. 40mg 125mg 500mg .. 40mg 125mg 500mg 1000mg . 1 125 2000mg .. 1 1000mg . 1000mg .. 40mg 125mg 500mg 1000mg 1 40 1000mg .. 8 .. 40mg 125mg 500mg 1000mg 8 30mg/Kg 15 . 45 23 .. 40mg 125mg 500mg 1000mg 1. 1 500 1000mg .. 2. 1 30mg/Kg 1000mg .. 40mg 125mg 500mg 1000mg 1 500 1000mg .. 40mg 125mg 1. 40 125mg . 40 80mg 4 6.. 2.. 4. 6 .. 40mg 125mg 500mg.)

7 250 500mg 1 1 5 . 1 3 4 .. 25 . 500mg/ 8mg/Kg/ 3 .. 2010 .. 40mg 125mg 500mg 1000mg .. Churg-Strauss .. 50 100mg 2 3 .. 75 100mg .. 50 150mg/ .. 50mg 150mg 450mg .. 2009 .. 30mg 100mg .. A . A B . A C . A .. B . D .. A 1 1 210mg/ . 3 3 1 .. B 1 1 100mg/ . 1 1 6 2 . 1 . C 1 1 80mg/ . 1 1 3 1 .. D 1 1 135mg/ . 24 3 1 .. A ( . 1 1 210mg/ ( ) 3 . 3 1 . ) C ( 1 1 80mg/ ( . ) 1 1 3 1 . ) .. 2009 .. 60mg 10 .. ( . ).. ( )1 60mg 1. 3 1 60 120mg .. ( )1 60mg 1. 3 1 60 120mg .. ( )1 60mg .. 1 2 1 180mg .. 25mg .. 75 100mg .. 25 50mg .. 25 50mg .. 100mg .. 1 1 2 .. 25 50mg .. kg .. 12 25mg .. 1 1000mg/ 30 . 1 3 4 . 1 .. 1 1250mg/ 30 . 1 2 3 . 1 .. NCCN 2012(National Complehensive Cancer Network). 2009 ( ).. 20 80 .. 60mg ( ) .. 75mg . 1 1 70mg .. 75mg . 1 1 70mg .. 1 1 75mg .. ( ). National Comprehensive Cancer Network(NCCN) Guidelines (NCCN . 2014 ( NCCN . ). (.))

8 ( .. 1.. 2.. 3.. 4.. 5.. 6.. 7.. MAC .. MAC .. MAC .. kg 10 15mg . kg 15mg .. kg . 10 15mg . kg 15mg .. kg 15mg .. kg . 15mg .. ( .. T20 T25 T20 T25. OD T20 T25 .. 40mg/ . 50mg/ . 60mg/ . mg mg . mg mg/ .. mg/ . mg/ .. 2011 . JOURNAL OF CLINICAL ONCOLOGY. NCCN Clinical Practice Guidelines in Oncology Asia Consensus Statements .. 500mg .. 1 250mg 1g .. 1 250 750mg .. 1 1 250 500mg .. 1 1 250 750mg .. SPECT . 500 1,000mg 15 17mg/kg .. 4 . 4 2015 4.. 250mg 1000mg .. 25mg 100mg .. 50mg 100mg . 200mg .. 1 5~15mg/kg . 5 1 1 5~ 1 1 . 1 5~15mg/kg . 1 1 . 1 5mg/kg 10~20 . 1 1 . 1 10~20mg/kg 1.. 1 5mg/kg .. 1 5~10mg/kg . 1~2 .. 1 1000mg/ 4~5 . 3 .. ( ) 1 100mg/ . 2 . 400mg/ . 600mg/ 22 . 2 2 . 1 250mg/ . 2 . 2600mg/ 24 . 1 6 2 . 1 . 1 200mg/ . 2 . 400mg/ . 2400~3000mg/ 46 . 2 .. 1 200mg/ 2.. 400mg/ . 2400mg/ 46 . 2 .. 1 250mg/ 2.. 1 1 600mg/ 3 . 1 6 2 . 1 .. 1 100mg/.))

9 2 . 400mg/ . 600mg/ 22 . 2 2 .. 1 250mg/ . 2 . 2600mg/ 24 . 1 6 2 . 1 . 1 200mg/ . 2 . 400mg/ . 2400 3000mg/ . 46 2 .. 1 200mg/ 2.. 400mg/ . 2400mg/ 46 . 2 .. A B A . B . A . 85 / 1 1 2 . 13 1 .. B . 130 / 1 1 2 . 20 1 .. 250 500mL .. -52 mFOLFOX6 .. NCCN Guidelines Gastric Cancer .. 1 100mg/ 2.. 400mg/ . 600mg/ 22 . 2 2 . 1 250mg/ 2.. 2600mg/ 24 . 1 6 2 1 .. 1 200mg/ 2.. 400mg/ . 2400~3000mg/ 46 . 2 .. A : . 85mg/ 1 1 2 . 13 1 .. 20mg .. 20~40mg 5~10mL .. 3~5 10 .. ( . 5~7 90 .. 20mg 5mL .. 4~12mg 1~3mL .. 40mg 100mg 40mg 100mg .. 100mg/5mL 100mg .. 10mg 25mg 50mg 10mg/20mL 25mg/50mL . 50mg/100mL .. 50mg 150mg 450mg .. - .. 1 1 100mg/. 1 3 4 2 . 1 . 1 1 150mg/. 2 2 3 3 . 1 . 1 1 40mg/. 3 1 2 3 . 2 1 .. 1 1 20mg/ . 5 1 2 . 1 1 . 1 1 180mg/. 2 1 .. 500mL . 90 .. 250mL . 60 . 100mL . 60 .. 1 60 100mg/ 5 . 3 1 .. 1 100mg/ 5 . 16 .. 1 100 150mg/ 3 5 . 3 1.)

10 15 20mg/ 1 1 5 . 2 1 .. 50 70mg/ 1 1 . 3 1 .. 25 35mg/ 1 1 . 1 1 .. 10 20mg/ 1 1 5 . 2 1 .. 70 90mg/ 1 1 . 3 1 .. 20mg/ 1 1 5 . 2 1 .. 100mg/ 1 1 . 3 1 .. 75mg/ 1 1 . 20 1 .. 25mg/ 60 . 1 2 3 1 .. 100mg/ 1 1 . 3 1 .. 50mg/ 1 1 . 3 1 .. 1 100mg/ 1 . 20 1 1 . 25mg/ 4 17 . 1 .. 60 100mg/ 1 1 . 3 1 .. 20mg/ 1 . 1 5 2 1 .. - .. 1 70mg/ . 30mg/. 1 2 3mg/ . 30mg / 70mg/ . 15 22 30mg/ . 3mg/ 1 4 .. 1 1 300 400mg/ . 4 1 .. 1 1 300 400mg/. 3 1 .. 635mg/ . 1 400mg/ 2 . 3 4 1 .. 1 10kg .. 560mg/ . 1 3 4 . 1 36 .. 250mL . 30 .. (NET) 2015 1 . (JNETS) .. 2014 . NCCN 2016 2 National Comprehensive Cancer Network(NCCN) . NCCN 2017 2 National Comprehensive Cancer Network(NCCN) .. 1 1 2 3 . 3 .. 1 1 8 15 . 4 .. 1 1 2 3 . 3 4 .. 80mg/ . 100mg/ .. 60mg/ . 60mg/ .. 5. 80mg/ .. 75 75 .. PCI . ST ST .. 75mg 1 1 . 50mg 1 1 .. PCI . 300mg 1 1 . 1 1 75mg .. 75mg 1 1 .. 300mg 1 1.